Vaccine News and Research

Latest Vaccine News and Research

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Researchers have developed a promising new anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)vaccine candidate that utilizes nanotechnology and shows robust, long-lived immunity in mouse models.

5 May 2021

Covid shot in the arm not enough to keep pharmacies in business

Tobin's pharmacy and department store had already stocked its shelves with Easter and Mother's Day items last spring, and the staff had just placed the Christmas orders.

5 May 2021

Study reveals missed opportunities to deliver essential preventive care to lupus patients

A new study published in Arthritis Care & Research indicates that few individuals with the autoimmune disease lupus who were publicly insured through Medicaid received recommended vaccines in 2000-2010.

5 May 2021

Stem cell therapy for COVID-19 and ARDS

In a review paper recently uploaded to the journal Biomedicine & Pharmacotherapy by Mahendiratta et al. (May 2021) the applicability of stem cells in treating severe SARS-CoV-2 infection is investigated, with regard to ARDS therapy.

5 May 2021

New book tackles the persistent and controversial questions about COVID

Ohio University mathematics professor Winfried Just's new book COVID-19: Unmasked - The News, the Science, and Common Sense tackles the persistent and sometimes controversial questions people have been asking about COVID-19 in a new, conversational way.

5 May 2021

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Researchers in the United States have shown that the Pfizer/BioNTech and Moderna messenger RNA (mRNA) vaccines are effective at generating T-cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 May 2021

Emergency physicians use heparin alternative to treat vaccine-induced blood clot

A new case report, detailed in Annals of Emergency Medicine, is the first known case of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) treated with a heparin alternative following the Centers for Disease Control and Prevention (CDC) guidance.

5 May 2021

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Researchers in the United States have identified short peptide sequences in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are immunogenic in a mouse model and may provide protection against viral variants.

5 May 2021

New vaccine candidate provides breakthrough in the fight against malaria

A malaria vaccine candidate tested on children in West Africa has shown an efficacy of around 77 per cent, say scientists, hailing it as a breakthrough in the fight against the disease.

4 May 2021

Study reveals no negative effect of SARS-CoV-2 BNT162b2 vaccination on male fertility

Researchers analyzed the sperm parameters of males undergoing fertility treatment and found no effect from the BNT162b2 mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.

4 May 2021

Can the absence of evidence of in-school SARS-CoV-2 transmission be taken as evidence of absence?

Research by scientists at the University of Texas at Austin, the Santa Fe Institute, and Fractal Therapeutics suggests infection rates in the surrounding community are not a reliable measure for estimating the level of risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in schools.

4 May 2021

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Moderna has announced Emergency Use Listing granted by the World Health Organization for its COVID-19 mRNA vaccine.

4 May 2021

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

A vexing problem in the development of vaccines has been the need to achieve the right glycosylation profile for the viral antigens. A new study, recently released as a preprint on the bioRxiv* server, shows how a sequential cell-free approach produced complex N-glycans from simpler types, in a one-pot reaction.

4 May 2021

Covid ‘doesn’t discriminate by age’: Serious cases on the rise in younger adults

After spending much of the past year tending to elderly patients, doctors are seeing a clear demographic shift: young and middle-aged adults make up a growing share of the patients in covid-19 hospital wards.

4 May 2021

Conspiracies beliefs about COVID-19 increased among users of conservative and social media

Belief in conspiracies about the COVID-19 pandemic increased through the early months of the U.S. outbreak among people who reported being heavy users of conservative and social media, a study by Annenberg Public Policy Center (APPC) researchers has found.

4 May 2021

Rapid and sensitive SARS-CoV-2 detection from saliva using CRISPR

In a paper recently uploaded to the preprint server medRxiv by Edward Málaga Trillo et al. (April 29th, 2021), these methods are tested in combination with CRISPR-Cas detection in the field, demonstrating a sensitivity and specificity of 93.8% and 99%, respectively.

4 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

Researchers in the United States and India have conducted a study demonstrating the real-world effectiveness of a single dose of Johnson & Johnson’s Ad26.COV2.S vaccine at preventing infection with severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

3 May 2021

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient’s age and disease severity.

3 May 2021

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

A new study, released as a preprint on the bioRxiv* server, reports promising results with the natural product hopeaphenol, which successfully prevented the entry of the virus into host cells.

3 May 2021

Vaccine News and Research

Latest Vaccine News and Research

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Covid shot in the arm not enough to keep pharmacies in business

Study reveals missed opportunities to deliver essential preventive care to lupus patients

Stem cell therapy for COVID-19 and ARDS

New book tackles the persistent and controversial questions about COVID

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Emergency physicians use heparin alternative to treat vaccine-induced blood clot

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

New vaccine candidate provides breakthrough in the fight against malaria

Study reveals no negative effect of SARS-CoV-2 BNT162b2 vaccination on male fertility

Can the absence of evidence of in-school SARS-CoV-2 transmission be taken as evidence of absence?

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

Covid ‘doesn’t discriminate by age’: Serious cases on the rise in younger adults

Conspiracies beliefs about COVID-19 increased among users of conservative and social media

Rapid and sensitive SARS-CoV-2 detection from saliva using CRISPR

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in